Aminosalicylates in inflammatory bowel disease
Abstract
Numerous clinical trials have supported the efficacy of aminosalicylates in the treatment of inflammatory bowel disease, particularly ulcerative colitis. There are few studies in paediatric patients addressing either pharmacokinetic properties or efficacy. There are a number of controversies in their clinical use, including: the optimum dose and dosing interval for induction and maintenance of remission, the most appropriate preparation given the clinical setting, the overall efficacy in Crohn’s disease, the efficacy in preventing post-operative recurrence of Crohn’s disease etc. A new oral mesalamine formulation, MMX (multi-matrix tablet), delivers mesalamine particularly to the distal colon even when given once daily. The tablet form still precludes use in small children.
Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
